Favorable survival with combined treatment in a metastatic breast cancer patient undergoing hemodialysis: A case report

Adjuvant trastuzumab for triple-positive breast cancer with chronic renal failure: A case report and review of literature

RATIONALE

Although the occurrence of combined renal insufficiency among patients with breast cancer is even rarer, it poses a significant challenge in the treatment of these patients. Treating such patients often requires both targeted and endocrine therapies. However, oncologists lack evidence-based guidelines for managing renal function in patients with renal insufficiency.

PATIENTS CONCERN

A 56-year-old menopausal female with a history of renal failure was diagnosed with triple-positive breast cancer and administered endocrine therapy and targeted therapy associated with hemodialysis after surgery.

OUTCOMES

Under the premise of regular dialysis, the patient successfully completed endocrine therapy and targeted therapy for 1 year.

DISCUSSION

Patients with advanced triple-positive breast cancer, including those undergoing hemodialysis, require a combination of anti-human epidermal growth factor receptor-2 and endocrine therapies, The side effects of these 2 treatment methods are worth considering in patients with renal insufficiency.

CONCLUSION

We report a case of triple-positive breast cancer in a patient undergoing hemodialysis. There was no difference in the treatment approach between patients with and without normal renal function.